HSHans-Joachim Schmoll

Hans-Joachim Schmoll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans-Joachim Schmoll has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).

    by Dirk Arnold, Ullrich Graeven, Christian A. Lerchenmuller, Brigitta Killing, Reinhard Depenbusch, Claus-Christoph Steffens, Salah-Eddin Al-Batran, Thoralf Lange, Georg Dietrich, Jan Stoehlmacher, et al.

    3503^ Background: The optimal maintenance strategy following combination chemotherapy plus Bev is still controversial. AIO KRK 0207 investigates whether after a 24-week standard induction with F//Ox/Bev, no continuation of therapy or continuation with Bev alone are non-inferior to FP plus Bev. Methods: Pts with mCRC and ‘standard’ eligibility criteria were enrolled. After 24 weeks of induction treatment with FP/Ox/Bev, pts without disease progression were randomized into one of the following arms: A) standard maintenance treatment with FP plus Bev; B) Bev alone; or C) no treatment. At first progression, re-induction of the initial treatment was planned. The primary endpoint was ‘time to failure of strategy’ (TFS), comprising maintenance plusre-induction after first progression. Sample size was calculated (one-sided alpha of 0.0125; power of 80%) to conclude non-inferiority compared with the FP plus Bev arm. Secondary endpoints included time to first progression (PFS1) and overall survival (OS). Results: 840 pts were enrolled, 473 randomized. Median follow-up is 27 months. After induction, 60% of pts had CR/PR, 40% SD. Median PFS1 in arms A, B, C were 6.2, 4.6 and 3.6 months (p< 0.0001; A vs C: HR 2.11, 95% CI 1.63-2.73; A vs B: HR 1.28, 95% CI 0.99-1.65; B vs C: HR 1.56, 95% CI 1.22-1.99), respectively. TFS favored arm A over arm C (HR 1.31, 95% CI 1.01-1.69, p=0.038) but without difference between arms A and B (HR 1.04,95% CI 0.81-1.36, p=0.74). However, upon first progression only 24% in arm A and 47 % in both arms B and C, received re-induction. After 200 documented events, preliminary OS is 23.4 months from randomization, without significant difference between treatment arms (p=0.69). Conclusions: Following 24 weeks of induction, active maintenance with both, FP plus Bev or Bev alone, show prolonged TFS over no treatment. Only a minority of patients received re-induction treatment as planned. With currently limited follow up, the different maintenance strategies had no impact on OS. Clinical trial information: NCT00973609.


  • Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

    by Dirkje Willemien Sommeijer, Qian Shi, Everardo D. Saad, Elisabeth Coart, Marc E. Buyse, Tomasz Burzykowski, Jeffrey P. Meyers, Tim Maughan, Richard A. Adams, Matthew T. Seymour, et al.

    3538 Background: To expedite drug development and improve treatment (trt) decisions, early indicators of trt efficacy are needed. We evaluated the pt-level association between early tumor shrinkage (ETS; ≥ 20% decrease from baseline), early objective tumor response (EOTR; CR/PR by RECIST), and early nonprogression status (EnPD;CR/PR/SD by RECIST) at 6, 8/9, or 12 weeks (wks) with OS, and compared these with standard endpoints (best overall response [BOR] and confirmed response [ConfR]) in pts treated with 1st-line CT. Methods: 16 phase III trials, including 10,962 pts on 5FU-LV/capecitabine alone or with oxaliplatin/irinotecan, from the ARCAD database were analyzed. Associations between early endpoints and OS were tested by stratified Cox models with a landmark approach. Prediction performance was compared by the C-index (c), a measure of relative accuracy to distinguish those at high versus low risk of death (higher value indicates better risk discrimination). Results: ETS and EOTR were significant predictors of OS with similar hazard ratios (HRs) to BOR and ConfR (p <0.0001; see Table). Pts without early progression (non-PD) showed the largest risk reduction (HRs ~ 0.3). Adjusting for age, performance status, number of metastases, and prior trt, significance remained. C-indices were similar across early endpoints, and similar to those for BOR and ConfR. Conclusions: Early responses are significantly associated with prolonged OS in mCRC pts on 1st-line chemotherapy. Early PD strongly correlates with an increased hazard of death. The pt-level prediction accuracy is as strong as for standard endpoints with the advantage of earlier tumor evaluation. Similar performance of ConfR implies the lack of utility for response confirmation. Formal surrogacy testing at trial level is ongoing.


  • Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).

    by Lindsay A. Renfro, Axel Grothey, David J. Kerr, Daniel G. Haller, Thierry Andre, Eric Van Cutsem, Leonard Saltz, Roberto Labianca, Charles L. Loprinzi, Steven R. Alberts, et al.

    3601 Background: The post-treatment survival experience of CC patients (pts) is well described in the literature, which states that cure is a probable outcome for some pts; formal survival comparisons vs. MGP are limited. Methods: Data from 32,745 pts enrolled to 25 randomized adjuvant trials conducted from 1977-2012 in 41 countries were pooled and 8 years of follow-up considered. The observed long-term survival experience of ACCENT pts was compared to the expected survival from a sex, age, country, and year MGP, overall and by stage (II, III), sex, treatment (surgery, 5FU, 5FU+oxaliplatin), age (< 70, 70+), year (pre/post 1990), and recurrence (Y/N). Comparisons were made at randomization (rand) and repeated conditional on survival to 1, 3, 5 years. CC/MGP equivalence was tested and observed Kaplan-Meier rates compared with expected MGP rates 3 years out from each landmark. Results: Within each ACCENT cohort, long-term survival of CC pts remained statistically worse than the MGP, though it improved over time given survival to certain landmarks. Among those surviving 5 years, stage II, oxaliplatin-treated, elderly, and recurrence-free pts achieved subsequent 3 year survival rates within 5% of the MGP; pts without recurrence had subsequent 3 yr. survival within 0.5% of MGP. Conclusions: Among CC pts on clinical trials who survive up to 5 years, subsequent long-term survival remains poorer than a MGP, but notably stage II, age 70+, received oxal, and recurrence-free pts achieve similar rates. These findings emphasize the need for access to quality care and the continued need for improved treatment/follow-up strategies.


  • Open Access

    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

    by Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera-Knorrenschild, Dieter Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer

    Purpose This phase II study evaluated the synthetic DNA-based immunomodulator and Toll-like receptor 9 agonist MGN1703 as maintenance treatment in metastatic colorectal carcinoma (mCRC). Methods Fifty-nine patients with mCRC and disease control after standard first-line chemotherapy were randomised to MGN1703 60 mg (N = 43) or placebo (N = 16). Results The hazard ratio (HR) for the primary endpoint [progression-free survival (PFS) from the start of maintenance] was 0.56 (95 % CI 0.29–1.08; P = 0.07) and 0.55 (95 % CI 0.3–1.0; P = 0.04) by independent and investigator review, respectively. MGN1703 significantly improved PFS measured from the start of induction therapy versus placebo on independent (HR 0.49; 95 % CI 0.26–0.94; P = 0.03) and investigator review (HR 0.50; 95 % CI 0.31–1.02; P = 0.02). Overall survival (OS) data remain immature (HR 95 %; 95 % CI 0.3–1.5; P = 0.29) with 28/43 patients alive after a medium follow-up of >17 months. Retrospective subgroup analysis showed a significant effect of MGN1703 on PFS versus placebo in patients with greater than median tumour size reduction and normalised carcinoembryonic antigen concentrations following induction therapy, and in patients with elevated activated NKT cells ≥3.08 %. Adverse events were mild to moderate and limited to injection-site reactions or linked to general immune system activation. Conclusions MGN1703 maintenance treatment was well tolerated and appears to induce durable and prolonged PFS and disease control in a subgroup of patients with mCRC following induction therapy. Activated NKT cells may be a predictive biomarker for selecting patients likely to benefit more from MGN1703.


  • IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.

    by Marina Tschaika, Hans-Joachim Schmoll, Jorge Riera-Knorrenschild, Dieter Nitsche, Jorg Trojan, H. Kröning, Fritz Albert Maiwirth, Marcel Reiser, Matthias Schroff, Ekaterina Weith, et al.

    633 Background: The synthetic DNA-based immunomodulator MGN1703 acts as an agonist of toll-like receptor 9. Based on promising data from a phase I study in patients with metastatic solid tumors including those with CRC, a phase II-III study was initiated in patients with advanced CRC having disease control after first-line therapy. The objective of the study is to assess efficacy and safety of the MGN1703 treatment in comparison to placebo. Methods: The IMPACT study is designed as a randomized double-blind placebo-controlled phase II-III study, which is conducted in patients with advanced CRC showing disease control after first-line therapy with standard chemotherapy regimen. The treatment is administered subcutaneously twice weekly in a ratio 2:1 (60 mg MGN1703 or placebo). The study is conducted in Germany, Austria, France, UK, Czech Republic and Russia, and 129 patients will be recruited into the study. The efficacy and safety of the study treatment will be evaluated based on extensive immunological tests, radiological assessment, safety laboratory results and assessments of the quality of life. The study treatment will be continued until tumor progression, intolerable toxicity, exclusion criteria or withdrawal of consent. Results: The majority of adverse events were assessed as not drug-related by the investigator. The remaining AEs include mild night sweat (not assessable), mild fever (at three occasions, possible related), and mild arthralgia (certain related) in one patient each. Three SAE have been reported so far of which one was assessed as probably drug-related – atypical pneumonia. Only in single patients local reactions such as mild redness and swelling at injection site were reported. No laboratory or clinical signs of autoimmunity or dose-limiting toxicities were reported, so far. Conclusions: With these preliminary safety results of the ongoing clinical study in patients with advanced CRC it could be shown that ttreatment with MGN1703 at the dosage of 60 mg is well tolerated and safe. Reported adverse events assessed as possibly drug-related belong to expected study drug reactions known for immune modulating drugs. These events were not accompanied by any signs of autoimmunity.


  • Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial

    by Patrick Jahn, Petra Renz, Joerg Stukenkemper, Katrin Book, Oliver Kuss, Karin Jordan, Ingrid Horn, Anette Thoke-Colberg, Hans-Joachim Schmoll, Margarete Landenberger

    The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing (SCION) program to reduce distressing anorexia, nausea, and emesis (ANE) in cancer patients undergoing chemotherapy. Two hundred eight patients receiving chemotherapy with moderate to high emetogenic potential participated in a cluster randomized trial on 14 wards in two German university hospitals. Additionally to standard antiemetic treatment, patients from the intervention wards received the SCION program consisting of four modules: advisory consultation, optimizing emesis prophylaxis, nutrition counseling, and relaxation. Patients from the control group received standard antiemetic treatment and standard care. Primary outcome was the group difference in ANE intensity assessed by Common Terminology Criteria for adverse events (CTCAE). The SCION program did not result in a significant difference in the incidence of ANE symptoms as compared to standard care: mean difference on CTCAE scale was 0.24 pts (95%CI, −1.17 to 1.66 pts; P = 0.733). No difference could be found regarding patients’ knowledge of side effects, self-care interventions, and agency. Health-related quality of life was significantly better for patients in the control group (mean difference 10.2 pts; 95%CI, 1.9 to 18.5; P = 0.017). Contrary to our expectations, the groups did not differ in ANE intensity caused by the overall low acute or delayed symptom intensity. Symptom hierarchy in cancer patients alters and challenges nursing interventions targeting the patients’ self-care strategies.


  • Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group

    by D. Arnold, T. Höhler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Wöll, T. Herrmann, A. Zubel, H.-J. Schmoll

    Background: This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer. Patients and methods: Cetuximab was administered weekly: 400 mg/m2 initial dose, then 250 mg/m2 and FUFOX: oxaliplatin 50 mg/m2, FA 500 mg/m2 and 5-FU as a 24-h infusion at either 1500 or 2000 mg/m2 administered for 4 weeks followed by a 1-week rest (one cycle). Results: Dose-limiting toxicity (grade 3 diarrhea) occurred in 3 of 14 assessable patients receiving 5-FU at standard 2000 mg/m2. This dose was administered to a further 25 patients. Cetuximab combined with FUFOX was generally well tolerated with the most common grade 3/4 adverse events being diarrhea (27%) and paresthesia (16%). The confirmed response rate for patients receiving 5-FU at standard 2000 mg/m2 (N = 41) was 56%, with a median duration of 9.3 months. Median progression-free and overall survival times including all 49 patients were 8.1 (95% confidence interval 6.0–9.7) and 28.2 months, respectively. Cetuximab pharmacokinetics seemed not to be different for combination with FUFOX compared with cetuximab/irinotecan combinations. Conclusion: This protocol is well tolerated and shows promising efficacy supporting further investigation.


  • Open Access

    Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report

    by Wieland Voigt, Karin Jordan, Christoph Sippel, Mroawan Amoury, Hans-Joachim Schmoll, Hans H Wolf

    Platelet counts exceeding 1.000 × 103/μl are usually considered secondary to another cause, particularly to chronic myeloproliferative disease (CMPD). Reactive thrombocytosis due to iron deficiency rarely exceeds platelet counts of 700 × 103/μl.